- 英文名称
- Ertugliflozin L-pyroglutamic acid
- 分子式
- C27H32ClNO10
- 分子量
- 566
- 中文别名
- 埃格列净L-焦谷氨酸; 埃格列净焦谷氨酸盐; 埃格列净共晶; 化合物T15244; (S)-5-氧吡咯烷-2-羧酸 (1S,2S,3S,4R,5S)-5-(4-氯-3-(4-乙氧基苄基)苯基)-1-(羟甲基)-6,8-二氧杂双环[3.2.1]辛烷-2,3,4-三醇盐; 艾托格列净; PF-04971729 L-pyroglutamic acid; Ertugliflozin L-pyroglutamic Acid (1:1); ERTUGLIFLOZIN PIDOLATE; PF-04971729 ((S)-5-oxopyrrolidine-2-carboxylic acid); (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (1:1) compound with (S)-5-oxopyrrolidine-2-carboxylic acid; (S)-5-Oxopyrrolidine-2-carboxylic acid compound with (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (1:1); ertugliflozin-L-pyroglutamic acid; cocrystal of (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol and L-pyroglutamic acid
- 用途
- 化学合成；作为2型糖尿病药物埃格列净（ertugliflozin）的中间体，用于其合成制备，该药物由辉瑞公司和默克公司共同开发，2017年12月获美国FDA批准上市，商品名为Steglatro，临床用于2型糖尿病成年患者治疗，目前未在国内上市。
